Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
Rhea-AI Summary
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's executive management will engage in a Fireside Chat scheduled for June 5, 2025, at 8:45 AM EDT in New York City. Investors and interested parties can access the webcast presentation through Akebia's investor relations website at ir.akebia.com after the conference concludes. The conference will run from June 3-5, 2025.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the trading session that priced this news, AKBA declined 1.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Akebia Executive Management will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 5 at 8:45 AM EDT.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The Jefferies Global Healthcare Conference will take place June 3-5, 2025, in New York City.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
